

Basik research of anti-angiogenesis and apoptosis targeted therapy

メタデータ	言語: jpn 出版者: 公開日: 2021-11-08 キーワード (Ja): キーワード (En): 作成者: Takahashi, Yutaka メールアドレス: 所属:
URL	https://doi.org/10.24517/00063160

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 International License.



2004 Fiscal Year Final Research Report Summary

Basik research of anti-angiogenesis and apoptosis targeted therapy

Research Project

Project/Area Number

15591392

Research Category

Grant-in-Aid for Scientific Research (C)

Allocation Type

Single-year Grants

Section

一般

Research Field

Digestive surgery

Research Institution

Kanazawa University

Principal Investigator

TAKAHASHI Yutaka Kanazawa University, Cancer Research Institute, Associate Professor, がん研究所, 助教授 (10179541)

Project Period (FY)

2003 – 2004

Keywords

Anti-angiogenesis / Apoptosis / CRT-11 / Low dose chemotherapy / Cachexia

Research Abstract

We compared the anti-tumor effects of CPT-11 and vessel density as a angiogenesis index, and apoptotic index of tumor between two different regimens groups, 100 mg/kg once a week (day 1 and 8) and 20 mg/kg five times a week (day 1, 2, 3, 4, 5, 8, 9, 10, 11, and 12) for two weeks. Vessel density was significantly less and the apoptotic index was significantly greater in tumors treated with 20 mg/kg 5 times per week of CPT -11 than those with 100 mg/kg once a week treatment. The combination effect of CPT-11 and anti-VEGF (vascular endothelial growth factor) antibody was observed only in tumors treated with 20 mg/kg 5 times per week of CPT -11. These effect were observed more remarkably in cachexia model.

These results suggest that divided low dose chemotherapy may induce the anti-angiogenesis as well as apoptosis. It will be applicable for patients with far advanced cancer, because these effect were observed much greater in cachexia model

[Journal Article] A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer.	2005	▼
[Journal Article] A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer.	2005	▼
[Journal Article] A pilot study of low dose, divided MTD of CPT-11 on 21 consecutive patients with metastatic colorectal or gastric cancer	2004	▼
[Journal Article] Angiogenesis of AFP producing gastric carcinoma : Correlation with frequent liver metastasis and its inhibition by anti-AFP antibody	2004	▼
[Journal Article] Oral administration of uracil-tegarfur (UFT) inhibits liver micrometastasis of human colon cancer in an orthotopic model	2004	▼
[Journal Article] A pilot study of low dose, divided MTD of OPT-11 on 21 consecutive patients with metastatic colorectal or gastric cancer.	2004	▼
[Journal Article] Angiogenesis of AFP producing gastric carcinoma : Correlation with frequent liver metastasis and its inhibition by anti-AFP antibody.	2004	▼
[Journal Article] Oral administration of uracil-tegarfur (UFT) inhibits liver micrometastasis of human colon cancer in an orthotopic model of nude mice and its early detection system	2004	▼
[Journal Article] Antibody against Vascular Endothelial Growth Factor (VEGF) Inhibits Angiogenic Switch and Liver Metastasis in Orthotopic Xenograft Model with Site-dependent Expression of VEGF.		▼
[Journal Article] Antibody against Vascular Endothelial Growth Factor (VEGF) Inhibits Angiogenic Switch and Liver Metastasis in Orthotopic Xenograft Model with Site-dependent Expression of VEGF.		▼

URL:

https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-15591392/155913922004kenkyu_seika_hokoku_